APA (7th ed.) Citation

Concordet, D., Gandia, P., Montastruc, J., Bousquet-Mélou, A., Lees, P., Ferran, A. A., & Toutain, P. (2020). Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? Clinical pharmacokinetics, 59(1), 1-5. https://doi.org/10.1007/s40262-019-00812-x

Chicago Style (17th ed.) Citation

Concordet, Didier, Peggy Gandia, Jean-Louis Montastruc, Alain Bousquet-Mélou, Peter Lees, Aude A. Ferran, and Pierre-Louis Toutain. "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?" Clinical Pharmacokinetics 59, no. 1 (2020): 1-5. https://doi.org/10.1007/s40262-019-00812-x.

MLA (9th ed.) Citation

Concordet, Didier, et al. "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?" Clinical Pharmacokinetics, vol. 59, no. 1, 2020, pp. 1-5, https://doi.org/10.1007/s40262-019-00812-x.